Real-world study of monoammonium glycyrrhizinate, cysteine, and sodium chloride injection for perioperative liver injury

Phase 4, open-label, single-arm trial of monoammonium glycyrrhizinate + cysteine + sodium chloride in Hepatic injury (not a disease, but a descriptive term for liver damage), sponsored by The First Affiliated Hospital of Sun Yat-sen University. Primary endpoint: Total recovery rate of liver function in subjects receiving hepatoprotective therapy after hepatectomy. Planned start Jan 2020; status: not yet recruiting.